These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2833951)

  • 1. Role of cyclic AMP in the action of dopaminergic D2 receptors of some endocrine glands in rats.
    Abu-Jayyab A; el-Denshary EE; Ageel AM; Dakkak MR
    Biosci Rep; 1987 Oct; 7(10):751-5. PubMed ID: 2833951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bromocriptine on cyclic-GMP contents of some endocrine glands and liver in rats.
    Abu-Jayyab A; el-Denshary EE; el-Hakim MM
    Biosci Rep; 1987 Jul; 7(7):559-62. PubMed ID: 2825825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Na+/K+-stimulated adenosine triphosphatase in the action of dopaminergic-D2 receptors of the liver in rats.
    Abu-Jayyab A; Mahgoub A
    Biosci Rep; 1987 Nov; 7(11):839-42. PubMed ID: 2835115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of dopamine D2 receptors linked to voltage-sensitive potassium channels reduces forskolin-induced cyclic AMP formation in rat pituitary cells.
    Memo M; Pizzi M; Belloni M; Benarese M; Spano P
    J Neurochem; 1992 Nov; 59(5):1829-35. PubMed ID: 1357100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bromocriptine on prostacyclin release and cyclic nucleotides on rat aortic and uterine tissues.
    Ageel AM; el-Tahir KE; Abu-Jayyab AR
    Prostaglandins; 1985 Sep; 30(3):369-81. PubMed ID: 2997843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor.
    Amiri Z; Katz Y; Weizman A; Bidder M; Snyder SH; Gavish M
    Biochem Pharmacol; 1993 Mar; 45(5):999-1002. PubMed ID: 8384854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
    J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine and bromocriptine inhibit cyclic AMP accumulation in the anterior pituitary: the effect of cholera toxin.
    Cronin MJ; Thorner MO
    J Cyclic Nucleotide Res; 1982; 8(4):267-75. PubMed ID: 6300209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine selectively inhibits angiotensin II-induced aldosterone secretion by interacting with D-2 receptors.
    Missale C; Memo M; Liberini P; Spano P
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1137-43. PubMed ID: 2458445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?
    Baptista T; Parada M; Hernandez L
    Pharmacol Biochem Behav; 1987 Jul; 27(3):399-405. PubMed ID: 2889218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention of 241 Am by some endocrine organs of the rat and its response to DPTA-treatment.
    Seidel A
    Int J Radiat Biol Relat Stud Phys Chem Med; 1973 Apr; 23(4):415-6. PubMed ID: 4540852
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of dopamine on voltage-dependent potassium currents in identified rat lactotroph cells.
    Lledo PM; Legendre P; Zhang J; Israel JM; Vincent JD
    Neuroendocrinology; 1990 Dec; 52(6):545-55. PubMed ID: 2149427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
    Zarrindast MR; Poursoltan M
    Br J Pharmacol; 1989 Apr; 96(4):843-8. PubMed ID: 2663110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in nalorphine-induced hyperprolactinaemia after bromocriptine or sulpiride administration.
    Barreca T; Magnani G; Sannia A; Rolandi E
    Eur J Clin Pharmacol; 1982; 22(4):375-6. PubMed ID: 7106173
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
    Lau YS; Runice C; Dowd F
    J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of prolactin, bromocriptine and sulpiride on estrogen and lactogenic receptors in the rat adrenal gland.
    Lüthy IA; Chiauzzi VA; Charreau EH; Calandra RS
    Acta Physiol Pharmacol Latinoam; 1984; 34(1):15-23. PubMed ID: 6089499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
    Enjalbert A; Bockaert J
    Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of dopaminergic ergot derivatives with cyclic nucleotide system.
    Spano PF; Saiani L; Memo M; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():95-102. PubMed ID: 6249093
    [No Abstract]   [Full Text] [Related]  

  • 20. Bromocriptine and sulpiride competitively inhibit estrogen binding to its receptor in the adrenal gland.
    Lüthy IA; Calandra RS
    Experientia; 1986 Feb; 42(2):136-8. PubMed ID: 3948967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.